

Portal Hypertension: Drug Development Pipeline Study, H1 2018

https://marketpublishers.com/r/P0D225E41D5EN.html

Date: March 2018

Pages: 31

Price: US\$ 895.00 (Single User License)

ID: P0D225E41D5EN

Abstracts

Portal Hypertension pipeline comprises of 8 drugs under development as of March 2018. Of these, 2 drugs are in Phase 1 and 5 drugs in phase 2 with no drugs in Phase 3. Further, 1 drug is in Pre-IND stage.

18 companies are developing the pipeline for Portal Hypertension. Of this, LinXis B.V. has the most recent stage drug in pipeline. 8 different mechanisms are being targeted for treatment of the condition.

Portal hypertension is the major cause for morbidity and mortality witnessed in patients suffering from liver cirrhosis. The condition is characterized by an increase in blood pressure levels in the portal venous system. It is one of the catastrophic complications associated with liver cirrhosis. As the vessels in the liver are blocked, blood does not smoothly pass through liver, resulting in elevated blood pressure. This results in growth of large and swollen veins in esophagus, stomach, rectum and umbilical areas.

The most comprehensive pipeline review "Portal Hypertension- Drug Development Pipeline Study" provides in-depth analysis and update information on Portal Hypertension pipeline drugs. Current status of all the drugs in the Portal Hypertension pipeline is provided in the research work.

The report provides detailed analysis of Portal Hypertension pipeline including companies involved, drugs in different stages of development, drug development details across regions (Region (North America, Europe, Asia Pacific and Rest of the World). Further, the Portal Hypertension report identifies aspects important in modifying industry market scenarios, increasing opportunities and list of potential companies that impact the Portal Hypertension industry.



Scope:

- All latest industry developments and their impact on projects and companies
- Complete overview of global Portal Hypertension therapy options and treatments
- The pipeline study reviews drug details for Portal Hypertension by developing companies, institutions, mechanism of action, Target, Route, Phase (pre-clinical/Discovery, Phase 1, Phase 2, Phase 3, Pre-Registration, IND/NDA), molecule
- Mergers, Acquisitions, licensing, co-development and project acquisition news for Portal Hypertension market
- Portal Hypertension drugs being developed in combination with other drugs are also detailed
- Company wise drugs listed with their current status, partners and news updates



Contents

1 TABLE OF CONTENTS

- 1.1 LIST OF FIGURES
- 1.2 LIST OF TABLES

2 EXECUTIVE SUMMARY

- 2.1 DISEASE OVERVIEW
- 2.2 PIPELINE SNAPSHOT
- 2.3 PIPELINE DRUGS BY PHASE
- 2.4 PIPELINE DRUGS BY COMPANY
- 2.5 PIPELINE DRUGS BY MECHANISM OF ACTION

3 PORTAL HYPERTENSION- COMPANY WISE PIPELINE ANALYSIS

- 3.1 Conatus Pharmaceuticals PIPELINE, H1 2018
- 3.2 Cumberland Pharmaceuticals PIPELINE, H1 2018
- 3.3 Galectin Therapeutics PIPELINE, H1 2018
- 3.4 Mezzion Pharma Co. Ltd. PIPELINE, H1 2018
- 3.5 LinXis B.V. PIPELINE, H1 2018
- 3.6 Novartis Pharmaceuticals PIPELINE, H1 2018
- 3.7 Ono Pharmaceuticals PIPELINE, H1 2018
- 3.8 Ferring Pharmaceuticals PIPELINE, H1 2018

4 PORTAL HYPERTENSION DRUG SNAPSHOTS

- 4.1 Emricasan Drug Details
 - 4.1.1 Snapshot
 - 4.1.2 Drug Overview
 - 4.1.3 Mechanism of Action
 - 4.1.4 Current Status
 - 4.1.5 Trial Details
- 4.2 Portaban Drug Details
 - 4.2.1 Snapshot
 - 4.2.2 Drug Overview
 - 4.2.3 Mechanism of Action
 - 4.2.4 Current Status



- 4.2.5 Trial Details
- 4.3 GR-MD-02 Drug Details
 - 4.3.1 Snapshot
 - 4.3.2 Drug Overview
 - 4.3.3 Mechanism of Action
 - 4.3.4 Current Status
 - 4.3.5 Trial Details
- 4.4 Udenafil Drug Details
 - 4.4.1 Snapshot
 - 4.4.2 Drug Overview
 - 4.4.3 Mechanism of Action
 - 4.4.4 Current Status
 - 4.4.5 Trial Details
- 4.5 LxL-001 Drug Details
 - 4.5.1 Snapshot
 - 4.5.2 Drug Overview
 - 4.5.3 Mechanism of Action
 - 4.5.4 Current Status
- 4.6 Serelaxin Drug Details
 - 4.6.1 Snapshot
 - 4.6.2 Drug Overview
 - 4.6.3 Mechanism of Action
 - 4.6.4 Current Status
 - 4.6.5 Trial Details
- 4.7 ONO 1266 Drug Details
 - 4.7.1 Snapshot
 - 4.7.2 Drug Overview
 - 4.7.3 Mechanism of Action
 - 4.7.4 Current Status
 - 4.7.5 Trial Details
- 4.8 FE 204205 Drug Details
 - 4.8.1 Snapshot
 - 4.8.2 Drug Overview
 - 4.8.3 Mechanism of Action
 - 4.8.4 Current Status
 - 4.8.5 Trial Details

5 APPENDIX



5.1 ABOUT VPA RESEARCH5.2 SOURCES AND RESEARCH METHODOLOGY



List Of Figures

LIST OF FIGURES

- Figure 1: Portal Hypertension Pipeline by Phase, H1- 2018
- Figure 2: Portal Hypertension Pipeline by Companies, H1- 2018
- Figure 3: Company wise Pipeline Drug Phases, H1- 2018
- Figure 4: Portal Hypertension Pipeline by Mechanism of Action, H1- 2018
- Figure 5: Mechanism wise Pipeline Drug Phases, H1- 2018



List Of Tables

LIST OF TABLES

- Table 1: Portal Hypertension Pipeline by Phase, H1- 2018
- Table 2: Portal Hypertension Pipeline by Companies, H1- 2018 (1)
- Table 3: Portal Hypertension Pipeline by Mechanism of Action, H1- 2018
- Table 4: Conatus Pharmaceuticals Portal Hypertension Pipeline, H1- 2018
- Table 5: Cumberland Pharmaceuticals Portal Hypertension Pipeline, H1-2018
- Table 6: Galectin Therapeutics Portal Hypertension Pipeline, H1- 2018
- Table 7: Mezzion Pharma Co. Ltd. Portal Hypertension Pipeline, H1- 2018
- Table 8: LinXis B.V. Portal Hypertension Pipeline, H1- 2018
- Table 9: Novartis Pharmaceuticals Portal Hypertension Pipeline, H1- 2018
- Table 10: Ono Pharmaceuticals Portal Hypertension Pipeline, H1- 2018
- Table 11: Ferring Pharmaceuticals Portal Hypertension Pipeline, H1- 2018



I would like to order

Product name: Portal Hypertension: Drug Development Pipeline Study, H1 2018

Product link: https://marketpublishers.com/r/P0D225E41D5EN.html

Price: US\$ 895.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name: Last name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/P0D225E41D5EN.html

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms

To pay by Wire Transfer, please, fill in your contact details in the form below:

Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Portal Hypertension: Drug Development Pipeline Study, H1 2018

and fax the completed form to +44 20 7900 3970

& Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below